Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00031187 | Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer | PHASE2 | COMPLETED | 160 | — | — | Oct 1, 2000 | Jul 1, 2003 | Oct 24, 2011 | 11 | United States |
| Name | Type | Description |
|---|---|---|
| SGN-15 (cBR96-doxorubicin immunoconjugate) | DRUG | - |
| Taxotere (docetaxel) | DRUG | - |
BRIEF: Patients must have pathologically confirmed prostate cancer, which is refractory to hormone therapy. There must be evidence of advancing disease, determined by increasing bidimensional or unidimensional measurable tumor or an increasing PSA with documented metastatic disease. Patients must ...